Rotigotine vs Pramipexole Dihydrochloride — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Nonergot Dopamine Agonist

Rotigotine

Brand: Neupro

First FDA approval: 2012-04-02

Nonergot Dopamine Agonist

Pramipexole Dihydrochloride

First FDA approval: 2010-10-08

Lowest NADACAcquisition cost floor across all NDCs

$28.21Per unit

$0.041Per unit

Average NADACAcross all dosage forms and strengths

$28.27Up to $28.30

$0.929Up to $2.84

Generic manufacturersActive ANDA holders — FDA Orange Book

00 total ANDAs filed

1694 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$128.5MFull year

—Full year

Part D claims (CY24)Total fills, all strengths

114K26K beneficiaries

—— beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$1,129Per claim, all NDCs

—Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

18Minimal friction

0Zero PA friction

Step therapy appliedPlan-NDC pairs requiring step therapy

48Limited friction

21Limited friction

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

NoBrand-only

Yes16 manufacturers